GRI Bio announced it has entered into a collaboration with the UK consortia, National Institute for Health and Care Research Respiratory Translational Research Collaboration to advance its leading NKT regulation technology to treat inflammatory, fibrotic and autoimmune diseases. “As a Company, we are dedicated to revolutionizing the way that inflammatory, fibrotic and autoimmune diseases like IPF are treated. The establishment of this collaboration represents another important step forward as we work to advance our clinical development programs. The NIHR Respiratory TRC offers cutting-edge translational research that we believe will assist in executing clinical studies underpinned by excellent scientific rigor. The expertise of the team, as well as the additional data examining the role of NKT cells in IPF from UK patients will be a valuable asset as we continue to advance GRI-0621,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. “
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GRI:
- GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
- GRI Bio files to sell 4.13M shares of common stock for holders
- GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
- GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
- GRI Bio announces article on iNKT cell review in Frontiers in Immunology